Retrospective-prospective blinded evaluation predicting efficacy of epirubicin by a multigene assay in advanced breast cancer patients.

Trial Profile

Retrospective-prospective blinded evaluation predicting efficacy of epirubicin by a multigene assay in advanced breast cancer patients.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2017

At a glance

  • Drugs Epirubicin (Primary)
  • Indications Advanced breast cancer
  • Focus Diagnostic use
  • Most Recent Events

    • 09 Jun 2017 According to a Medical Prognosis Institute media release, data from this trial presented at the 2017 Annual meeting of American Society of Clinical Oncology (ASCO).
    • 09 Jun 2017 New trial record
    • 04 Jun 2017 Results (n=137) from this trial published in a Medical Prognosis Institute Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top